新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 百时美施贵宝 » BMS与Ambrx达成抗体偶联药物开发合作

BMS与Ambrx达成抗体偶联药物开发合作

来源:生物谷 2013-05-07 22:06

2013年5月7日讯 /生物谷BIOON/ --百时美施贵宝(BMS)昨日宣布,已与Ambrx制药达成了一项合作协议,利用Ambrx的蛋白质药化(Protein Medicinal Chemistry,PMC)技术发现和开发新型抗体偶联药物。

根据协议,Ambrx将收到一笔1500万美元的预付款,同时还将有望从所合作项目产生的每一个产品中获得高达9700万美元的开发、监管、销售里程碑款项。BMS将获得所合作产品的全球开发及商业化权利,Ambrx还将有资格获得产品销售的特许权使用费。

Ambrx与BMS于2011年9月签署了2项单独的合作协议,研究、开发及商业化由Ambrx公司蛋白质药化技术创造的生物制剂,包括靶向于成纤维细胞生长因子(FGF-21)及松弛激素(Relaxin)的生物制剂,目前这些制剂正由BMS开发用于II型糖尿病及心脏衰竭的治疗。(生物谷bioon.com)

英文原文:
Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates

Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

Under terms of the agreement, Ambrx will receive an upfront payment of $15 million, funding for discovery and research activities, and potential development, regulatory and sales based milestone payments of up to $97 million per product resulting from the collaboration. Bristol-Myers Squibb will receive worldwide rights to develop and commercialize products resulting from the collaboration, and Ambrx is eligible to receive royalties on net sales. Additional terms were not disclosed.

"Bristol-Myers Squibb is a global biopharmaceutical leader with expertise developing and commercializing novel medicines for the treatment of cancer and other diseases, and we are pleased to enter into a third collaboration with the company to include another aspect of our technology platform," said Lawson Macartney, Ph.D., chief executive officer of Ambrx. "We look forward to working together to further utilize Ambrx's technology to discover and advance these antibody drug conjugates for oncology indications."

Ambrx and Bristol-Myers Squibb entered into two separate agreements in September 2011 to research, develop and commercialize biologics created with Ambrx's protein medicinal chemistry technology. These therapeutic candidates, which target the Fibroblast Growth Factor 21 (FGF-21) protein for the potential treatment of type 2 diabetes, and the Relaxin hormone for the potential treatment of heart failure, are being developed by Bristol-Myers Squibb.

About Ambrx
Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including antibody drug conjugates, bispecific antibodies and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. In addition to its three collaborations with Bristol-Myers Squibb, Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Astellas, Merck, Eli Lilly and Company and several undisclosed companies.  Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit www.ambrx.com.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库